Issues of implementation of WHO Guidelines on fortification of food grade salt with iodine for the prevention and control of iodine deficiency disorders in countries of Eastern Europe and Central Asia are discussed.

The article is dedicated to the discussion about to guidelines for the treatment of hypothyroidism prepared by the American thyroid association task force on thyroid hormone replacement.

The article is dedicated to the discussion about part of European thyroid association guidelines for the management of subclinical hypothyroidism in children

The article is dedicated to the modern paradigm of the management of nodular goiter, negative tendencies in real clinical practice.

Dyslipidemia is a frequent condition in patients with hypothyroidism which determines possible need for statin use in treatement. However, both hypothyroidism and statin use can lead to myopathy and rhabdomyolysis so safety concerns are important for clinical decision. Current article is a review of publications, clinical guidelines and drug labels which are related to the problem of statin safety in patients with hypothyroidism. Recommendations are given for use of statin in patients with compensated and decompensated hypothyroidism based on review of data.

This review will provide an overview of a novel phenomenon in medicine and endocrinology known as microchimerism (MC). MC is defined as the long-term presence of genetically distinct populations of cells in peripheral blood and tissues of individual. This condition may be caused by the transplacental bidirectional cell trafficking between mother and fetus during pregnancy. Other sources are the passage from a twin or a vanished twin and iatrogenic interventions such as organ transplantation and blood transfusion.

Long-term consequences of MC and its influence on woman's health are under active investigation. Recent studies have shown a broad spectrum of its biological effects either beneficial or adverse.

MC has been suggested to play a key role in the pathogenesis of autoimmune diseases. It is assumed that microchi-meric cells could initiate a "graft versus host" or "host versus graft" reactions. MC has been extensively studied in autoimmune thyroid diseases (AITD). MC could explain the higher prevalence of AITD in females and frequent manifestation during the postpartum period.

It is proposed that microchimeric cells could reduce the risk of cancer development and be a part of tissue repair. MC has also been investigated in papillary thyroid cancer. Further studies of this phenomenon are mandatory to get more insights about its role in thyroid cancer and AITD development. This could provide novel therapeutic, preventive or prognostic perspectives regarding these diseases.

The article contains abstracts of actual modern international researches dedicated to management of various thyroid pathology and influence of accompanying states.

With the use of minimally invasive techniques (MIM) treated 489 patients with cystic-colloid nodes. Laser-induced thermotherapy (LITT) — 371 patient, Ethanol destruction of ED — 54 patients, 63 — combined technique (KombiLITT). Dynamics of node size was assessed in 356 patients (72.8%). LITT — 252 patients, ED — 50 patients KombiLITT — 52 patients. LITT used in the treatment of solid structure nodes. Additional nodes up to 1 cm³ after LITT large part diminished by more than 50% (43 of 76). Additional nodes 1—2 cm³ also decreased more than half by more than 50% (39 of 67). Among nodules greater than 4 cm³ was not a single site that would reduce in volume by more than 75%. However, most of them decreased by more than 25%. The algorithm of differential treatment of cystic nodes. ED performed in 54 patients with cystic destruction of a site more than 70%. Marked decrease in the average volume at 4.68 ± 2.25 cm³ to 1.15 ± 0.9 cm³. KombiLITT performed in 63 patients with cystic cavity 20 to 70%. Volume units decreased at 7.98 ± 4.56 cm³ to 1.87 ± 0.9 cm³. LITT performed in 30 patients with major nodes and cystic cavities less than 20% of the site. Marked decrease in the volume of units at 2.89 ± 1.25 cm³ and 1.42 ± 0.8 cm³. LITT held 31 patients with small cystic nodes to 1 cm³. Marked decrease in size at 0.69 ± 0.23 cm³ to 0.29 ± 0.12 cm³. It has been shown that changes in thyroid status after MIM operations does not occur.

Purpose: to analyze in a comparative perspective certain factors influencing recurrent differentiated thyroid cancer (DTC) in patients with an increasing concentration of serum thyroglobulin (Tg) and serum antithyroglobulin antibodies (TgA) in the blood serum.

Patients and methods. The outcomes of 31 patients with a tumor marker of recurrent DTC after more than 6 months since the first radioiodine ablation (RAI) were analyzed. A follow-up on the group of patients was realized in the form of thyroid bed ultrasonography and dynamic control of Tg and TgA in the blood serum every 3 months during the first year after the first and second RAI and every 6 months later. The group selection criteria was the identification of a DTC recidivism tumor marker, which is characterized by the increase of more than 5 ng/ml in the face of synthetic thyroid hormone analogues intake and more than 2.5 ng/ml in the face of a suppressive therapy cessation, as well as an increase in titer in Al-TG over 20 IU/ml. The given values were regarded as a relapse of the disease after 6 months after the first RAI.

Results. In 70% of all cases a tumor spread to the regional lymph nodes was found. 21% of relapses were observed in the group of patients with a level of TSH below 50 IU/ml. In 35% of cases the ultrasonography showed the presence of thyroid tissue in the thyroid bed projection and the enlargement of lymph nodes in the neck in 5 patients (16.61%) of relapses were identified in patients with an extraorganic spread of the tumor. In 30% of cases the first RAI activity was less than 3.0 GBq. A DTC recidivism tumor marker was observed more often 65 in patients with less than 5% of the RFID tags all over the body after the initial administration of the therapeutic activity of I¹³¹.

Conclusion. Major risk factors for the DTC recidivism tumor marker are (1) save-on surgical stage of combined treatment, (2) the spread of a tumor process on regional lymph nodes in the neck, the presence of significant thyroid balance after the operation, according to thyroid scintigraphy, (3) insufficient profundity of hypothyroidism before RAI, (4) administration of activity of I¹³¹ less than 3.0 GBq with the first RAI, (5) ignoring the suppressive therapy regime after RAI.